IP Library Granted Patent US 8,183,353
Granted Patent B2
US 8,183,353 · App. 11/923,888 · Granted May 22, 2012

Breast cancer prognostics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,183,353
App. No.
11/923,888
Granted
May 22, 2012
Kind
B2
Abstract

A method of providing a prognosis of breast cancer is conducted by analyzing the expression of a group of genes. Gene expression profiles in a variety of medium such as microarrays are included as are kits that contain them.

Claims (3)

1. A kit for determining the prognosis of a breast cancer patient comprising materials for detecting isolated nucleic acid sequences, their complements, or portions thereof comprising a combination of genes including all of Seq. ID. No. 1-56 and wherein said kit further includes materials that indicate up regulation of genes of Seq. ID. No. 1 to 26 and 56 together with down regulation of genes of Seq. ID. No. 27 to 55 such that said patient has a poor prognosis.

2. The kit of claim 1 comprising reagents for conducting a microarray analysis.

3. The kit of claim 1 further comprising a medium through which said nucleic acid sequences, their complements, or portions thereof are assayed.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded May 31, 2022
From: BANK OF AMERICA, N.A.
To: ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC
Reel/Frame 060219/0571 →
SECURITY INTEREST Recorded Jul 3, 2014
From: ORTHO-CLINICAL DIAGNOSTICS, INC; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 033276/0104 →